Genmab A/S Dkk (GNMSF) 37.4000 $GNMSF
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014: 23 Companies and 33 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/p7dbhq/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Biogen Idec Inc. - Cognosci, Inc. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Genmab A/S - GlaxoSmithKline plc - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Nuron Biotech, Inc. - Opexa Therapeutics, Inc. - Receptos, Inc. - RedHill Biopharma Ltd. - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - Trophos SA - XenoPort, Inc. Drug Profiles: - laquinimod sodium - dimethyl fumarate - laquinimod sodium - fingolimod hydrochloride - ocrelizumab - interferon beta-1b - daclizumab - RPC-1063 - Epigallocatechin Gallate - GSK-239512 - siponimod - tabalumab - firategrast - ponesimod - plovamer acetate - estriol - imilecleucel-t - olesoxime - ofatumumab - RNS-60 - (rifabutin clarithromycin clofazimine) - diazoxide - MT-1303 - Boswellic Acids - VAY-736 - MEDI-551 - interferon beta-1b pegylated - XP-23829 - Pegylated Interferon-Beta-1b - COG-133 For more information visit http://www.researchandmarkets.com/research/p7dbhq/relapsing
Cervical Cancer - Pipeline Review, H1 2014: 48 Company and 82 Drugs Profiled
M2 - Wed May 07, 10:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wpfpds/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved: - 3SBio Inc. - Advanced Cancer Therapeutics - Advaxis, Inc. - Amorfix Life Sciences Ltd. - Antigen Express, Inc. - ApoVax, Inc. - Arbor Vita Corporation - Azaya Therapeutics Incorporated - Bionor Pharma ASA - CEL-SCI Corporation - CZ BioMed Corp - Centre de Regulacio Genomica - Chong Kun Dang Pharmaceutical Corp. - Coridon Pty Ltd - Daiichi Sankyo Company, Limited - Dendreon Corporation - EyeGene, Inc. - F. Hoffmann-La Roche Ltd. - Formune S.L. - Genetic Immunity, Inc - Genexine, Inc. - Genmab A/S - Genticel - Gilead Sciences, Inc. - GlaxoSmithKline plc - Helix BioPharma Corp. - ISA Pharmaceuticals B.V. - Indian Immunologicals Limited - LondonPharma Ltd - Med Discovery SA Drug Profiles: - hot water extract of mycobacterium tuberculosis - bevacizumab - (tegafur gimeracil oteracil potassium) - etirinotecan pegol - interferon alpha-2b - ADXS-HPV - ProCervix - hot water extract of mycobacterium tuberculosis - celecoxib - Triapine - exatecan mesylate - buparlisib hydrochloride - nimotuzumab - GSK-2141795 trametinib - TG-4001 - pazopanib hydrochloride - CIGB-228 Vaccine - CIGB-300 - nedaplatin [paclitaxel albumin-bound] - TA-HPV Vaccine - mapatumumab - artemether - HLA-A-0201 Restricted Specific Epitope Peptide Vaccine - ISA-101 - HuMax-TF ADC - PDS-0101 - docetaxel liposomal - Leukocyte Interleukin Injection - everolimus - GSK-2256098 For more information visit http://www.researchandmarkets.com/research/wp...cal_cancer
Genmab Announces Financial Results for the First Quarter of 2014
GlobeNewswire - Wed May 07, 10:12AM CDT
Interim Report First Quarter 2014
Genmab Announces New Phase III Study of Daratumumab in Multiple Myeloma & Improves 2014 Financial Guidance
GlobeNewswire - Thu May 01, 2:09PM CDT
Company Announcement
First Quarter 2014 Net Sales Figures for Arzerra
GlobeNewswire - Wed Apr 30, 6:16AM CDT
Company Announcement
GSK and Genmab Receive FDA Approval for Arzerra(r) (ofatumumab) as First-Line Treatment in Combination with Chlorambucil for Patients with Chronic Lymphocytic Leukemia (CLL) for Whom Fludarabine-Based Therapy is Considered Inappropriate
GlobeNewswire - Thu Apr 17, 2:52PM CDT
Company Announcement
Passing of Genmab A/S' Annual General Meeting
GlobeNewswire - Wed Apr 09, 10:18AM CDT
Company Announcement
Ventana signs companion diagnostic agreement with international biotech for antibody drug conjugate program
PR Newswire Europe - Thu Apr 03, 9:01AM CDT
Ventana Medical Systems, Inc. [http://www.ventana.com/] (Ventana), a member of the Roche [http://www.roche.com/index.htm] Group, today announced that it has entered into an agreement with Genmab A/S, Copenhagen, Denmark for the development of companion diagnostic tools for Genmab's HuMax-TF(R)-ADC antibody drug conjugate (ADC) program. As part of the agreement, Ventana will provide its expertise and services towards the development of an immunohistochemistry (IHC) companion diagnostic test for the detection of tissue factor (TF) in patient tumor samples. The TF assay will be developed for possible designation as the screening test in clinical trials involving HuMax-TF(R)-ADC.
Genmab Reaches $22 Million Milestone in Daratumumab Collaboration with Janssen
GlobeNewswire - Wed Mar 26, 5:58PM CDT
Company Announcement
Genmab Announces Phase III Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
GlobeNewswire - Tue Mar 04, 11:48PM CST
Company Announcement
Genmab 2013 Annual Report
GlobeNewswire - Tue Mar 04, 10:23AM CST
Genmab A/S (Copenhagen:GEN) today published its Annual Report for 2013. Below is a summary from the report of business progress and financial performance for the year, and financial outlook for 2014. The full report is attached as a PDF file and can be found on the investor section of the company's website, www.genmab.com.
Arzerra(R) Fourth Quarter and Full Year 2013 Net Sales Figures
GlobeNewswire - Wed Feb 05, 6:15AM CST
Company Announcement
Major Shareholder Announcement
GlobeNewswire - Wed Jan 29, 12:57PM CST
Company Announcement
Can Genmab (GNMSF) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 02, 7:47AM CST
Genmab could be an interesting play for investors because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
Why Genmab A/S (GNMSF) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 31, 7:58AM CST
Genmab performance and growth prospects can be a good choice for the investors.
GSK and Genmab Receive Priority Review from FDA for Arzerra(r) (ofatumumab) as 1st Line Treatment for Chronic Lymphocytic Leukemia (CLL)
GlobeNewswire - Tue Dec 17, 3:00PM CST
Company Announcement
Genmab to Receive Milestone Payment in DuoBody Platform Collaboration with Janssen - Financial Guidance Improved
GlobeNewswire - Fri Dec 06, 9:23AM CST
Company Announcement
Genmab Reaches Fourth Milestone in Lundbeck Collaboration
GlobeNewswire - Fri Dec 06, 6:45AM CST
Company Announcement
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014: 23 Companies and 33 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/p7dbhq/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Biogen Idec Inc. - Cognosci, Inc. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Genmab A/S - GlaxoSmithKline plc - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Nuron Biotech, Inc. - Opexa Therapeutics, Inc. - Receptos, Inc. - RedHill Biopharma Ltd. - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - Trophos SA - XenoPort, Inc. Drug Profiles: - laquinimod sodium - dimethyl fumarate - laquinimod sodium - fingolimod hydrochloride - ocrelizumab - interferon beta-1b - daclizumab - RPC-1063 - Epigallocatechin Gallate - GSK-239512 - siponimod - tabalumab - firategrast - ponesimod - plovamer acetate - estriol - imilecleucel-t - olesoxime - ofatumumab - RNS-60 - (rifabutin clarithromycin clofazimine) - diazoxide - MT-1303 - Boswellic Acids - VAY-736 - MEDI-551 - interferon beta-1b pegylated - XP-23829 - Pegylated Interferon-Beta-1b - COG-133 For more information visit http://www.researchandmarkets.com/research/p7dbhq/relapsing
Cervical Cancer - Pipeline Review, H1 2014: 48 Company and 82 Drugs Profiled
M2 - Wed May 07, 10:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wpfpds/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved: - 3SBio Inc. - Advanced Cancer Therapeutics - Advaxis, Inc. - Amorfix Life Sciences Ltd. - Antigen Express, Inc. - ApoVax, Inc. - Arbor Vita Corporation - Azaya Therapeutics Incorporated - Bionor Pharma ASA - CEL-SCI Corporation - CZ BioMed Corp - Centre de Regulacio Genomica - Chong Kun Dang Pharmaceutical Corp. - Coridon Pty Ltd - Daiichi Sankyo Company, Limited - Dendreon Corporation - EyeGene, Inc. - F. Hoffmann-La Roche Ltd. - Formune S.L. - Genetic Immunity, Inc - Genexine, Inc. - Genmab A/S - Genticel - Gilead Sciences, Inc. - GlaxoSmithKline plc - Helix BioPharma Corp. - ISA Pharmaceuticals B.V. - Indian Immunologicals Limited - LondonPharma Ltd - Med Discovery SA Drug Profiles: - hot water extract of mycobacterium tuberculosis - bevacizumab - (tegafur gimeracil oteracil potassium) - etirinotecan pegol - interferon alpha-2b - ADXS-HPV - ProCervix - hot water extract of mycobacterium tuberculosis - celecoxib - Triapine - exatecan mesylate - buparlisib hydrochloride - nimotuzumab - GSK-2141795 trametinib - TG-4001 - pazopanib hydrochloride - CIGB-228 Vaccine - CIGB-300 - nedaplatin [paclitaxel albumin-bound] - TA-HPV Vaccine - mapatumumab - artemether - HLA-A-0201 Restricted Specific Epitope Peptide Vaccine - ISA-101 - HuMax-TF ADC - PDS-0101 - docetaxel liposomal - Leukocyte Interleukin Injection - everolimus - GSK-2256098 For more information visit http://www.researchandmarkets.com/research/wp...cal_cancer
Genmab Announces Financial Results for the First Quarter of 2014
GlobeNewswire - Wed May 07, 10:12AM CDT
Interim Report First Quarter 2014
Genmab Announces New Phase III Study of Daratumumab in Multiple Myeloma & Improves 2014 Financial Guidance
GlobeNewswire - Thu May 01, 2:09PM CDT
Company Announcement
First Quarter 2014 Net Sales Figures for Arzerra
GlobeNewswire - Wed Apr 30, 6:16AM CDT
Company Announcement
GSK and Genmab Receive FDA Approval for Arzerra(r) (ofatumumab) as First-Line Treatment in Combination with Chlorambucil for Patients with Chronic Lymphocytic Leukemia (CLL) for Whom Fludarabine-Based Therapy is Considered Inappropriate
GlobeNewswire - Thu Apr 17, 2:52PM CDT
Company Announcement
Passing of Genmab A/S' Annual General Meeting
GlobeNewswire - Wed Apr 09, 10:18AM CDT
Company Announcement
Ventana signs companion diagnostic agreement with international biotech for antibody drug conjugate program
PR Newswire Europe - Thu Apr 03, 9:01AM CDT
Ventana Medical Systems, Inc. [http://www.ventana.com/] (Ventana), a member of the Roche [http://www.roche.com/index.htm] Group, today announced that it has entered into an agreement with Genmab A/S, Copenhagen, Denmark for the development of companion diagnostic tools for Genmab's HuMax-TF(R)-ADC antibody drug conjugate (ADC) program. As part of the agreement, Ventana will provide its expertise and services towards the development of an immunohistochemistry (IHC) companion diagnostic test for the detection of tissue factor (TF) in patient tumor samples. The TF assay will be developed for possible designation as the screening test in clinical trials involving HuMax-TF(R)-ADC.
Genmab Reaches $22 Million Milestone in Daratumumab Collaboration with Janssen
GlobeNewswire - Wed Mar 26, 5:58PM CDT
Company Announcement
Genmab Announces Phase III Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
GlobeNewswire - Tue Mar 04, 11:48PM CST
Company Announcement
Genmab 2013 Annual Report
GlobeNewswire - Tue Mar 04, 10:23AM CST
Genmab A/S (Copenhagen:GEN) today published its Annual Report for 2013. Below is a summary from the report of business progress and financial performance for the year, and financial outlook for 2014. The full report is attached as a PDF file and can be found on the investor section of the company's website, www.genmab.com.
Arzerra(R) Fourth Quarter and Full Year 2013 Net Sales Figures
GlobeNewswire - Wed Feb 05, 6:15AM CST
Company Announcement
Major Shareholder Announcement
GlobeNewswire - Wed Jan 29, 12:57PM CST
Company Announcement
Can Genmab (GNMSF) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 02, 7:47AM CST
Genmab could be an interesting play for investors because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
Why Genmab A/S (GNMSF) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 31, 7:58AM CST
Genmab performance and growth prospects can be a good choice for the investors.
GSK and Genmab Receive Priority Review from FDA for Arzerra(r) (ofatumumab) as 1st Line Treatment for Chronic Lymphocytic Leukemia (CLL)
GlobeNewswire - Tue Dec 17, 3:00PM CST
Company Announcement
Genmab to Receive Milestone Payment in DuoBody Platform Collaboration with Janssen - Financial Guidance Improved
GlobeNewswire - Fri Dec 06, 9:23AM CST
Company Announcement
Genmab Reaches Fourth Milestone in Lundbeck Collaboration
GlobeNewswire - Fri Dec 06, 6:45AM CST
Company Announcement
